Business Context and Reporting Period
This Form 6-K filing by Autolus Therapeutics Plc, dated February 11, 2021, reports the entry into an underwriting agreement for a public offering of American Depositary Shares (ADSs). The Company is a foreign private issuer headquartered in London, United Kingdom.
Key Financial Metrics and Transaction Details
- Offering Size: 14,285,715 ADSs representing an equal number of ordinary shares.
- Offering Price: $7.00 per ADS.
- Gross Proceeds: Approximately $100.0 million.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 2,142,857 ADSs.
- Underwriters: J.P. Morgan Securities LLC and Wells Fargo Securities, LLC.
- Expected Closing: On or about February 12, 2021.
The filing text does not provide specific values for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the capital raise transaction.
Material Changes
The primary material change is the execution of the Underwriting Agreement on February 9, 2021, facilitating the $100.0 million equity raise. This transaction was made pursuant to an effective shelf registration statement on Form F-3 filed in July 2019.
Outlook, Risks, and Management Commentary
Management expects the offering to close subject to customary conditions. The filing includes standard forward-looking statements regarding the closing of the offering, noting that actual results may differ due to market risks and uncertainties. Investors are directed to the Company's Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings for a detailed discussion of risk factors.
Key Facts for Investor Verification
- Confirmation of the final closing date and total net proceeds after underwriting discounts.
- Whether the underwriters exercised the 30-day over-allotment option for an additional 2,142,857 ADSs.
- The specific allocation of the $100.0 million gross proceeds as disclosed in subsequent financial reports.
- Any dilution impact on existing shareholders resulting from the issuance of 14,285,715 new ADSs.